

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 28, 2024

REZOLUTE, INC.
(Exact Name of Registrant as Specified in Charter)

Nevada
(State or Other Jurisdiction
of Incorporation)

001-39683
(Commission
File Number)

27-3440894
(I.R.S. Employer
Identification No.)

275 Shoreline Drive, Suite 500, Redwood City, CA 94065
(Address of Principal Executive Offices, and Zip Code)

650-206-4507
Registrant's Telephone Number, Including Area Code

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	RZLT	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On June 28, 2024, Rezolute, Inc. (the "Company") made available the RZ402 data presentation with the Appendix attached thereto, on the data presentation page of its website. The RZ402 data presentation was first presented during the Company's May 21, 2024 webcast for investors of the Company and the media. Subsequently, the Company added an Appendix to the RZ402 data presentation on June 28, 2024. A copy of the RZ402 data presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REZOLUTE, INC.

DATE: June 28, 2024

By: */s/Nevan Charles Elam*
Nevan Charles Elam
Chief Executive Officer



Topline Results: RZ402-201 Phase 2 Study in Patients with Diabetic Macular Edema (DME)

May 21, 2024

Forward-Looking Statements

This presentation, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "prove," "potential," "seek," "strive," "try," or future or conditional verbs such as "predict," "could," "may," "likely," "should," "will," "would," or similar expressions. These forward-looking statements include but are not limited to statements regarding the RZ402 study, the ability of RZ402 to become an effective treatment for diabetic macular edema, the effectiveness or future effectiveness of RZ402 to become an effective treatment for diabetic macular edema, and statements regarding clinical trial timelines for RZ402. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in the Rezolute's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the SEC's website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.

Introduction

Inhibiting Plasma Kallikrein: Oral-Systemic Approach to Diabetic Macular Edema (DME)

Kallikrein-Kinin System (KKS): an Alternative Pathway to Target DME

- KKS is a 1st line defense against vascular injury
 - Promotes vascular permeability, inflammation, and coagulation
- Diabetes injures retinal blood vessels
 - PK over-activation leads to inflammation and macular edema
- Preclinical and clinical data implicate KKS as a VEGF-independent cause of DME
- A PKI should target the vascular site of action
 - RZ402 concentrations in blood correlate with DME response in animal model
 - May explain lack of effect of intravitreal PKIs


RZ402: An Oral Once Daily PKI for DME

- Possible treatment alternative for patients with suboptimal response to anti-VEGF therapies
- Intended as monotherapy or combination with anti-VEGF injections
- Oral dosing and systemic levels enables sustained drug exposures for kallikrein inhibition at retinal blood vessel site of action
- Added advantage of treating both eyes

Potential systemic treatment and opportunity for early intervention to support prevention or treatment of DME

RZ402 Phase 2 Study Topline Results

RZ402-201 Study Design Overview



Endpoints

○ Primary

- Safety, including AEs and SAEs, ocular exams, and systemic evaluations (e.g. vitals, ECG, labs)
- Efficacy – Change in Central Subthreshold Thickness (CST) from baseline compared to placebo
 - A recognized and objective Phase 2 anatomic marker of macular edema

○ Secondary

- Change in best corrected visual acuity (BCVA) from baseline compared to placebo
- Change in Diabetic Retinopathy Severity Score (DRSS) score compared to placebo
 - Exploratory and not expected to change in a 3-month study
- Repeat-dose PK profile of RZ402
- Fellow eye evaluation (in evaluable eyes not treated with anti-VEGF)

Key Eligibility Criteria

- Mild to moderate non-proliferative diabetic retinopathy with center-involved DME
- No more than 3 anti-VEGF injections previously
 - None within 8 weeks of randomization
- CST of ≥ 320 microns in males and ≥ 305 microns in females
- BCVA ≤ 78 letters on Early Treatment Diabetic Retinopathy Study (ETDRS)
- Stable glycemic control

Study Disposition and Populations

- 94 Participants Enrolled
 - 84 Completed, 10 Discontinued (5 for anti-VEGF rescue, 5 Withdrew Consent)
- 12 Participants had an eligible/evaluable fellow-eye
 - 94 Study Eyes, 12 Fellow Eyes
- Rescue and/or use of anti-VEGF was uncommon in the study eye overall

	50 mg	200 mg	400 mg	Placebo	Total
Enrolled Participants (Study Eyes)	23	23	24	24	94
Evaluable Non-Study eyes	0	2	4	6	12
Completed Participants	18	22	21	23	84
Early Terminated	5	1	3	1	10
Subject Withdrawal	2	1	2	0	5
Rescued with anti-VEGF	3	0	1	1	5

Participant Demographics and Baseline Characteristics

	50 mg (N=22)	200 mg (N=23)	400 mg (N=24)	Placebo (N=24)	Total (N=93)
Age (Mean, Range)	61 (53-76)	60 (31-74)	62 (35-75)	64 (47-74)	62 (31-76)
Gender (n, M / F)	12 / 10	10 / 13	15 / 9	16 / 8	53 (57%) / 40 (43%)
Diabetes History (Mean Duration [y]; HbA1c (%))	16; 7.4%	17; 7.9%	18; 7.3%	13; 7.3%	16; 7.5%
Study Eye Prior Anti-VEGF History (yes / no [%]) Average number of Injections	5 / 17 0.4	6 / 17 0.5	6 / 18 0.5	5 / 19 0.3	22 (24%) / 71 (76%) 0.4
Study Eye CST (mean, Range [µm])	464 (314-625)	438 (313-824)	429 (329-629)	408 (307-680)	434 (307-824)
Study Eye BCVA (mean, Range [letters])	69 (53-81)	70 (27-81)	70 (56-80)	69 (72-80)	70 (27-81)
DRSS Score (n, %) ≤43 (Moderate NPDR or better) ≥47 (Moderately Severe NPDR or worse)	16 (73%) 6 (27%)	21 (91%) 2 (9%)	24 (100%) 0	23 (96%) 1 (4%)	84 (90%) 9 (10%)

Low rates of pre-study anti-VEGF use in this patient population underscore that invasive treatments (anti-VEGF) are often deferred

RZ402 Was Safe and Well-Tolerated


- AEs were generally mild and rates were comparable to placebo
- No adverse events of note that are associated with other PKIs
 - No liver enzyme abnormalities
 - No significant GI events
- SAEs were uncommon and judged by the Investigator as not related to study drug
- ECG, vitals, and safety labs unremarkable

Treatment-Emergent Adverse Events	50 mg (n=23)	200 mg (n=23)	400 mg (n=24)	Placebo (n=24)	Total (n=94)
Subjects with AEs	13 (57%)	11 (48%)	13 (54%)	12 (50%)	49 (52%)
Total AEs (mostly mild)	24	26	21	17	88
Subjects with SAEs (coincided with severe)	0	1	2	0	3
Total SAEs	0	2	2	0	4
Deaths	0	0	0	0	0
Discontinuations due to AE	0	0	0	0	0
AEs by System Class/Term					
Hypertension	2	2	0	1	5
Gastrointestinal	4	1	3	3	11
Hepatic Enzyme Increases	0	0	0	0	0
Ocular	1	0	3	3	7
diabetic retinopathy	1	0	1	1	3
cataract	0	0	0	1	1
dry eye	0	0	0	1	1
eye pain	0	0	1	0	1
vitreoretinal traction	0	0	1	0	1


Preliminary Pharmacokinetics

- Dose-dependent but not dose-proportional increases in concentrations
- Expected concentrations were achieved and profile supports once daily oral dosing
- Concentration which resulted in a 90% reduction in macular edema in rodent models of DME (EC90) was exceeded at all dose levels in the present study
 - Assuming equivalent potency translation to humans, near maximal kallikrein inhibition was likely achieved across all doses


Primary Endpoint Met: Clinically Significant Reduction in CST




Participant CST Responses at 200 mg RZ402 Compared to Placebo



Representative OCT Scan for 200 mg Participant:
 • Significant intraretinal fluid and cysts at Baseline



↓ >100 micron CST improvement and cyst resolution



Additional Endpoints and Summary of Results

- **Achieved good systemic exposure and safe and well-tolerated**
- **First PKI and oral therapy of any class to demonstrate a CST improvement in patients with DME**
 - CST improved significantly in Study Eye at all doses compared to placebo (up to ~50 microns)
 - A pre-specified sub-analysis by CST severity indicates that CST improvements were even larger (~75 microns) in subset of patients with more baseline edema (CST values \geq 400 microns)
 - CST declined in most patients who received 200 mg RZ402, including clinically significant improvements from baseline in more than 20% of participants, compared to none in placebo, with high rates of worsening
- **Maximal response at 200 mg likely explained by drug saturation of plasma kallikrein activity**
- **Vision is not expected to improve or correlate with CST changes over a 3-month study**
 - Observed improvements in CST predictive of visual improvements in a longer duration study
- **Five RZ402 treated participants at 200 mg (20%) experienced a 1-step improvement in DRSS compared to 1 participant in placebo**
- **Minority of non-study eyes retrospectively met eligibility criteria, and anti-VEGF use was not restricted in the non-study eye**
 - It is likely that both eyes would benefit simultaneously, in a study designed to assess this
- **Results support advancement into late-stage development (longer duration Phase 2b/3 studies)**


Thank You

Appendix

June 28, 2024


Repeat-Dose Pharmacokinetics

- Dose-dependent but not dose-proportional increases in concentrations
- Target concentrations achieved and profile supports once daily oral dosing
- Concentration which resulted in a 90% reduction in macular edema in rodent models of DME (EC90) was exceeded at all dose levels in the present study
 - Assuming equivalent potency translation to humans, maximal kallikrein inhibition was likely achieved at all doses




Primary Endpoint Met: Clinically Significant Reduction in Study Eye CST

- All doses achieved clinically relevant reduction in CST, the primary biomarker associated with DME
- Active arms demonstrated non-progression as compared to placebo






RZ402 Led to Significant CST Improvements at All Dose Levels in Equivalent Patients (Baseline CST ≥400 microns)



Proportion of Patients Achieving a Clinically Significant CST Improvement


Representative OCT Scan for 200 mg anti-VEGF naïve participant:
Significant intraretinal fluid and cysts at Baseline



REZOLUTE  | 21

Potential for Binocular Benefit Demonstrated in the Limited Evaluable Non-Study Eyes


- Most Fellow eyes were not eligible for efficacy evaluation due to lack of DME or excessive pre-study anti-VEGF use
- CST Improvements in Fellow Eyes with DME and new onset anti-VEGF use (during study)
- Binocular benefit would be an expected advantage of an effective oral, systemic treatment



REZOLUTE 

CST Declines and Trajectory Would Predict Continued Vision Improvement Over a Longer Study Period

- Acute vision increase in placebo group was artifact (no CST correlation)
- Trend of correlation between CST improvement and BCVA improvement is an encouraging signal in this short study
- Subsets of patients with similar disease severity in anti-VEGF studies showed modest BCVA improvement (~ 5-letters) after 1 year of treatment¹



1. NEJM (Feb. 18, 2015): Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema, The Diabetic Retinopathy Clinical Research Network

